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ATTR, amyloid transthyretin  
AL, amyloid immunoglobulin light chains 
DPD, 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid 
EF, ejection fraction 
HMDP, hydroxymethylenediphosphonate 








Cardiac amyloidosis is increasingly recognized as an important cause of heart failure with preserved 
ejection fraction (EF) (1) and carries a high morbidity and mortality.(2, 3) Emerging imaging methods 
have facilitated earlier diagnosis(4-6) and improved prognostication(7, 8) and management. The 
diagnostic criteria for cardiac amyloidosis, however, need to be updated to include these novel imaging 
tools.  
A multi-societal writing group with expertise in cardiovascular imaging and cardiac amyloidosis has been 
assembled by the American Society of Nuclear Cardiology (ASNC) with representatives from the 
American College of Cardiology (ACC), the American Heart Association (AHA), the American Society of 
Echocardiography (ASE), the European Association of Nuclear Medicine (EANM), the Heart Failure 
Society of America (HFSA), the International Society of Amyloidosis (ISA), the Society of Cardiovascular 
Magnetic Resonance imaging (SCMR), and the Society of Nuclear Medicine and Molecular Imaging 
(SNMMI). This writing group has established consensus recommendations on imaging cardiac 
amyloidosis from this panel of multidisciplinary experts. Part 1 documents the evidence base for 
multimodality imaging in cardiac amyloidosis and defines standardized imaging protocols. Part 2 has the 
following aims: 
1) Develop consensus diagnostic criteria for cardiac amyloidosis incorporating advanced 
echocardiography, cardiovascular magnetic resonance (CMR), and radionuclide imaging.  
2) Identify consensus clinical indications for noninvasive imaging in cardiac amyloidosis to guide 
patient management through a rigorous application of the modified Delphi method. 
3) Address the appropriate utilization of echocardiography, CMR, and radionuclide imaging in 
these clinical scenarios. 
DIAGNOSTIC CRITERIA, CLINICAL INDICATIONS, AND APPROPRIATE UTILIZATION 
Expert consensus criteria were developed based on histologic, clinical, and imaging features with 
accompanying certainty of recommendation. The appropriate utilization of multiple imaging modalities 
was assessed using clinical scenarios that represent diverse patient presentations and address the 
diagnostic and prognostic capabilities of noninvasive imaging. The goal of this document is to determine 
which modalities may be reasonable for a specific indication rather than to identify one test that is best.  
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In order to accomplish this goal, a rating panel of clinical experts in cardiac amyloidosis was assembled. 
As recommended by the RAND-UCLA Appropriateness Manual, this group included representatives from 
relevant clinical societies, all of whom have extensive expertise in the management of cardiac 
amyloidosis.(9) The group was recruited internationally from diverse geographical locations. All group 
representatives practice in academic settings, which is typical given the clinical complexity of this 
disorder. Experts with extensive imaging expertise were expressly excluded from this panel to prevent 
bias in the scoring process, as experts with expertise in a single imaging modality might tend to rate 
their favored imaging modality as more appropriate than the remainder. The final ratings panel included 
seven clinical experts.(9) This group developed expert consensus recommendations on criteria for the 
diagnosis of cardiac amyloidosis via histologic, imaging, and cardiac biomarkers. The rating panel then 
engaged in an exercise using the modified Delphi technique for a robust evaluation of 
appropriateness.(10) 
Indication Development 
A standardized approach was used to ensure inclusion of the majority of clinical scenarios encountered 
in the evaluation and management of cardiac amyloidosis. Despite best efforts, however, the writing 
group acknowledges that clinical presentations vary, and not every relevant clinical scenario is 
represented. These scenarios were organized into several broad categories representing key areas of 
cardiac amyloidosis clinical care: 
• Assessment for cardiac involvement in asymptomatic individuals; 
• Screening for cardiac amyloidosis in patients with symptomatic heart failure; 
• Evaluation of biopsy-proven light chain (AL) and amyloidogenic transthyretin (ATTR) cardiac 
amyloidosis; 
• Follow-up testing for new or worsening cardiac symptoms; 
• Other diverse clinical scenarios/conditions; and 
• Prior testing suggestive of cardiac amyloidosis.  
Once a final list was developed, the larger writing group, comprised of imaging experts in the various 




Once the indications were finalized, the rating panel scored them independently. For each indication, 
the rating panel was asked to rate its appropriateness in the evaluation and management of cardiac 
amyloidosis. The following definition of appropriate use was adapted from prior appropriate use 
documents (11-13): 
An appropriate imaging study is one in which the expected incremental information, combined 
with clinical judgement, exceeds the expected negative consequences by a sufficiently wide 
margin for a specific indication that the procedure is generally considered acceptable care and a 
reasonable approach for the indication.(14) 
 
The rating group used a scale from 1 to 9. These scores were divided into three general categories: 
Appropriate (A), May Be Appropriate (M), or Rarely Appropriate (R) in accordance with published 
appropriate use criteria methodology and prior appropriate use documents.(12, 15-17) 
 
Appropriate (Score 7–9) 
 
An indication scored from 7 to 9 represents an appropriate option for management of patients in this 
population due to benefits generally outweighing risks; it should be viewed as an effective option for 
individual care plans, although the imaging procedure may not always be necessary depending on 
physician judgement and patient-specific preferences (i.e., the procedure is generally acceptable and is 
generally reasonable for the indication). 
 
May Be Appropriate (Score 4–6) 
 
An indication scored from 4 to 6 is considered at times an appropriate option for management of 
patients in this population due to variable evidence or agreement regarding the risk-benefit ratio, 
potential benefit based on practice experience in the absence of evidence, and/or variability in the 
population; the effectiveness of this indication for individual care must be determined by a patient’s 
physician in consultation with the patient based on additional clinical variables and judgement along 
with patient preferences (i.e., the procedure may be acceptable and may be reasonable for the 
indication). A categorization of May Be Appropriate may also imply that further research and/or patient 




Rarely Appropriate (Score 1–3) 
 
An indication scored from 1 to 3 is rarely an appropriate option for management of patients in this 
population for this clinical indication due to a lack of a clear benefit/risk advantage; it is rarely an 
effective option for individual care plans; exceptions should have documentation of the clinical reasons 
for proceeding with this care option (i.e., procedure is not generally acceptable and is not generally 
reasonable for the indication). 
The division of the scores into these three broad categories is somewhat arbitrary, and the raters were 
instructed to consider the numeric range as a continuum. Recognizing that there is variability in many 
patient factors, local practice patterns, and a lack of data on use of imaging across clinical scenarios and 
indications, the rating panel members were asked to independently rate the appropriateness of using 
each imaging modality for the general category and the specific clinical indication based on the best 
available evidence, including guidelines and key references wherever possible.(10) 
After rating the indications independently, the total results were tabulated, and each rater was provided 
with their individual scores and de-identified scores from all other panel members. The panel was 
convened for conference calls for discussion of each indication. The clinical indications were modified if 
needed based on the discussion. This meeting was facilitated by non-rating representatives of the 
writing panel who served as unbiased moderators and facilitated group dynamics to optimize the 
process. The moderators were free of significant relationships with industry and were unbiased relative 
to the topics under consideration. Following the meeting, panel members were asked to independently 
provide their scores for each clinical indication in a second round of ratings, taking into consideration 
the discussion from the call. For indications with continued significant dispersion of scores, a second 
conference call and third round of ratings occurred. 
Median scores were calculated. A median panel score of 7 to 9 without disagreement was considered 
“Appropriate.” A median panel score of 1 to 3 without disagreement was considered “Rarely 
Appropriate.” A median panel score of 4 to 6 or any median with disagreement was classified as “May 
Be Appropriate.” Agreement was classified as having no more than two panelists provide ratings in an 




The following list of assumptions to be followed was adapted from methodology recommendations and 
prior appropriate use documents and was communicated to the expert rating panel members prior to 
their rating of the indications.(12, 15, 17, 18) 
 
1.  All imaging studies are assumed to be locally available and to be performed in accredited imaging 
laboratories in accordance with published criteria for quality cardiac diagnostic testing using state-
of-the-art, certified imaging equipment. 
2. All imaging is assumed to be performed according to the standard of care as defined by the peer-
reviewed medical literature. 
3. All interpreting physicians are qualified and certified to supervise the imaging procedure and 
appropriately report the findings. 
4. In clinical scenarios, the clinical status listed is assumed to be valid as stated (asymptomatic patients 
are truly asymptomatic) and no extenuating circumstances are to be taken into consideration 
(patient willingness to receive treatment, clinical stability) unless specifically noted. 
5. Appropriateness should be rated independently of the appropriateness of any prior diagnostic 
imaging that may have been performed. 
6. All patients are assumed to be receiving optimal therapy conforming to current standards of care, 
including contemporary heart failure therapy and cardiovascular risk-factor modification, unless 
specifically noted. 
7. Imaging indicated for surveillance to assess disease progression or response to therapy is assumed 
to be performed solely because the indicated time period elapsed rather than due to any change in 
clinical circumstances. 
8. Radiation risk was not considered. Although theoretical concerns have been raised that diagnostic 
imaging-related ionizing radiation may result eventually in an increased risk of cancer in the exposed 
population, this has not been proven. Moreover, in this population with high risk for heart failure 
and neuropathy, the benefit of a small dose of radiation was felt to outweigh the risk, especially 
when compared to a strategy with invasive endomyocardial biopsy. This risk can be minimized by 
preventing inappropriate use and by optimizing studies with the lowest radiation dose possible.(19) 
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9. Cost of the imaging procedures is not to be considered in accordance with recommended 
appropriateness scoring methods.(9) Cost is recognized to be an important issue from a policy 
perspective, but expert physician appropriateness rating has been shown to agree with cost-
effectiveness models.(20, 21)  
Definitions 
1. No cardiac symptoms 
The absence of the following symptoms was used to indicate that no cardiac symptoms are present. 
These include chest pain, fatigue, effort intolerance, shortness of breath, palpitations, 
dizziness/lightheadedness, syncope, orthopnea, paroxysmal nocturnal dyspnea, bloating, leg swelling, 
leg or jaw claudication. 
2. TTR gene carrier 
A TTR gene carrier refers to individuals who harbor one of the more than 120 mutations in the 
transthyretin gene that have been associated with the development of transthyretin amyloidosis.(22) 
3. Recurrent testing 
Recurrent testing refers to performance of the same imaging modality more than once, excluding non-
diagnostic studies, to identify cardiac involvement in the setting of prior negative testing; the interval 
between studies is not addressed. 
4. Biopsy-proven AL cardiac amyloidosis 
The diagnosis of AL amyloidosis requires a positive tissue biopsy showing amyloid deposits in the 
presence of clinical, imaging, or laboratory signs of organ involvement. The amyloid deposits should 
exhibit a characteristic affinity for Congo red staining with birefringence under polarized light. Typing of 
AL amyloidosis is confirmed on immunohistochemistry and/or mass spectroscopy. Electron microscopy 
of amyloid deposits is rarely performed but reveals prototypic rigid, nonbranching 10- to 12-nm width 
fibrils. Amyloid deposits can be detected at accessible sites, such as abdominal fat, bone marrow, or 
minor salivary glands, and the biopsy of the involved organ is not always necessary.(23) 
5. Abnormal NT-proBNP and Troponin T 
Cardiac biomarkers (N terminal – pro brain natriuretic peptide, NT-proBNP and troponins) are used for 
staging with different cutoffs.(24-26) In AL amyloidosis, NT-proBNP has >99% diagnostic sensitivity, with 
all patients with heart involvement having an elevated (≥332 ng/L) NT-proBNP.(27) 
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6. Monoclonal gammopathy of uncertain significance (MGUS) 
A premalignant, clonal plasma cell disorder characterized by the presence of a usually small monoclonal 
(M) protein and <10% clonal plasma cell clones in the bone marrow in the absence of multiple myeloma 
or related lymphoplasmacytic malignancies.(28, 29) 
7. Abnormal free light chains (FLCs) 
Abnormal FLCs are defined by an abnormal serum Kappa and Lambda immunoglobulin FLC ratio. The 
reference interval of FLC ratio may vary by the assay method used or in the setting of renal failure. The 
reference range of the FLC ratio as measured by Binding Site is between 0.26 and 1.65 in patients with 
normal renal function or between 0.31 and 3.7 in patients with renal failure. The reference range of the 
FLC ratio as measured by Siemens is between 0.31 and 1.56. 
8. Symptomatic heart failure 
Symptomatic heart failure refers to patients who have New York Heart Association (NYHA) Class II or 
greater symptoms adapted from Dolghin et al. (30) from original source(31). 
9. Unexplained heart failure 
Unexplained heart failure refers to heart failure without a known etiology, in particular, ischemic heart 
disease or valvular heart disease. 
10. Increased wall thickness 
Echo mean left ventricular (LV) wall thickness of >12mm with no other known cardiac cause.(23) 
11. Preserved LV ejection fraction 
Heart failure with preserved ejection fraction is defined per ACC/AHA heart failure guidelines as an LV 
ejection fraction of ≥40%.(32) 
12. Low flow aortic stenosis 
A low-flow aortic stenosis was defined as low transvalvular mean aortic gradient (≤40 mm Hg) or stroke 
volume index of <35 mL/m2 in the context of reduced LV ejection fraction (classical low flow) or 
preserved LV ejection fraction (paradoxical low flow).(33) 
13. Unexplained peripheral sensorimotor neuropathy 
Patient-reported paresthesias typical for this type of neuropathy in which no known cause has been 
identified (e.g., diabetes, alcohol abuse, or toxicity).  
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14. Known or suspected familial amyloidosis 
Documented amyloidosis in one or more closely related family members, such as a parent, brother or 
sister, uncle or aunt, and particularly so if a mutation of an amyloidogenic protein has been identified. In 
addition, an unexplained clinical picture of peripheral polyneuropathy and/or cardiomyopathy in several 
family members in a number of generations.  
15. Biopsy-proven ATTR cardiac amyloidosis 
Endomyocardial biopsy showing amyloid deposits, which are confirmed on immunohistochemistry 
and/or mass spectroscopy to be transthyretin.  
16. Contraindication to Cardiac Magnetic Resonance (CMR) 
As the CMR scanner generates a very powerful static magnetic field, certain implanted cardiac devices 
and ferromagnetic prostheses may pose a safety concern from movement, arrhythmia induction, or 
tissue heating from the magnetic fields. Each device must be evaluated on an individual basis for safety 
before proceeding with CMR. Due to a potential risk of nephrogenic systemic fibrosis, gadolinium use is 
contraindicated in individuals with estimated glomerular filtration rate (GFR) <30 ml/min/1.73m2.(34) 
17. Unexplained bilateral carpal tunnel syndrome 
Carpal tunnel syndrome is defined as a symptomatic compression neuropathy of the median nerve at 
the level of the wrist, characterized physiologically by evidence of increased pressure within the carpal 
tunnel and decreased function of the nerve at that level.(35) Bilateral carpal tunnel syndrome in the 
absence of rheumatoid arthritis or known trauma is defined as unexplained. 
18. Unexplained biceps tendon rupture 
Biceps tendon rupture in the absence of trauma, such as severe heavy lifting. 
 
19. Echo, CMR, or 99mTc-PYP/DPD/HMDP imaging study suggestive of cardiac amyloidosis 
An echocardiogram, CMR, or 99mTc-pyrophosphate (99mTc-PYP)/ 99mTc-3,3-diphosphono-1,2-
propanodicarboxylic acid (99mTc-DPD)/ 99mTc-hydroxymethylenediphosphonate (99mTc-HMDP) 
radionuclide imaging study with findings of cardiac amyloidosis as specified in Table 1, Expert Consensus 
Recommendations for Diagnosis of Cardiac Amyloidosis. 
Diagnostic Criteria for Cardiac Amyloidosis 
The current diagnosis of cardiac amyloidosis is not standardized. A multicenter consensus paper has 
proposed a diagnostic algorithm for the evaluation of ATTR cardiac amyloidosis incorporating 
echocardiography, CMR, and bone-avid radiotracers;(36) however, no formal diagnostic criteria have 
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been reported. An international consensus document on AL amyloidosis defines cardiac involvement by 
either endomyocardial biopsy or by systemic biopsy demonstrating AL amyloid and elevated LV wall 
thickness on echocardiography without alternative cardiac cause.(23) However, advances in noninvasive 
imaging and cardiac biomarkers in cardiac amyloidosis during the past two decades have led to 
improved methods of assessment beyond echocardiographic wall thickness. These tools have extensive 
validation in the literature, as described above, but were not included in the consensus document. They 
allow for more sensitive and earlier detection of disease. Therefore, there is a need for updated 
diagnostic criteria that incorporate these novel methods. Expert consensus recommendations for 
criteria for diagnosis of cardiac amyloidosis are provided in Table 1 with accompanying certainty of 
recommendation. Cardiac amyloidosis is confirmed with a positive endomyocardial biopsy for amyloid 
fibrils. In the absence of endomyocardial biopsy-proven disease, cardiac amyloidosis can be diagnosed 
using a combination of extracardiac biopsy, 99mTc-PYP/DPD/HMDP scintigraphy, myocardial uptake of 
targeted positron emission tomography (PET) amyloid tracers, and echocardiographic and CMR findings 
as shown in Table 1. In the absence of a clonal plasma cell process, 99mTc-PYP/DPD/HMDP scintigraphy 
consistent with ATTR cardiac amyloidosis combined with consistent echo or CMR findings obviates the 
need for invasive endomyocardial or extracardiac biopsy. 
Appropriate Utilization of Multimodality Imaging in Cardiac Amyloidosis 
The appropriate utilization ratings for echocardiography, CMR, and radionuclide scintigraphy (99mTc-
PYP/DPD/HMDP) for the 32 clinical indications are provided in Table 2. There were 30 evaluable 
indications for echocardiography, of which 27 were rated as “Appropriate” and 3 “May Be Appropriate.” 
Cardiac magnetic resonance likewise had 30 evaluable indications, of which 19 were rated as 
“Appropriate,” 9 as “May Be Appropriate,” and 2 as “Rarely Appropriate.” 99mTc-PYP/DPD/HMDP 
scintigraphy had 31 evaluable indications, of which 10 were “Appropriate,” 6 were “May Be 
Appropriate,” and 15 “Rarely Appropriate.” Echocardiography was rated as “Appropriate” for all 
assessed clinical indications except for some more frequent intervals of assessment of cardiac response 
to therapy or disease progression, which were rated as “May Be Appropriate.” Except for new onset 
symptomatic heart failure, CMR had more mixed ratings. 99mTc-PYP/DPD/HMDP scintigraphy was rated 
as “Appropriate” or “May Be Appropriate” for all indications other than those involving suspected light-




Although cost considerations, radiation risk, and availability of technology were not considered during 
the rating process, the rating panel did want to emphasize that these issues may influence the choice of 
imaging modality, particularly with regard to the frequency of repeat testing. The panel also wanted to 
stress the importance of consideration of referral to specialized amyloidosis centers, particularly in 
familial amyloidosis, AL cardiac amyloidosis, or for consideration of novel therapies. 
Clinical Scenario #1: Identifying Cardiac Involvement: No Cardiac Symptoms 
For asymptomatic gene carriers, echocardiography and radionuclide scintigraphy (99mTc-
PYP/DPD/HMDP) were rated as “Appropriate,” while CMR was rated “May Be Appropriate.” Because the 
age of onset and phenotypic manifestation of disease vary by the type of mutation, imaging was 
determined by the panel to be appropriate in some situations but not for others, resulting in a rating of 
“May Be Appropriate.” In particular, the panel discussed that extracellular volume (ECV) assessment by 
CMR has the potential to identify disease earlier in asymptomatic gene carriers compared with 
echocardiography. For asymptomatic patients with elevated cardiac biomarkers and either biopsy-
proven systemic AL amyloidosis or MGUS with abnormal FLC levels, echocardiography and CMR were 
rated as “Appropriate,” but 99mTc-PYP/DPD/HMDP scintigraphy was “Rarely Appropriate.” The panel 
discussed that the magnitude of biomarker abnormality should play a role in determining the use of 
imaging. In particular, due to the high prevalence of MGUS, as well as ATTR wild-type (ATTRwt) in older 
individuals, use of imaging may be guided by serum biomarker levels, particularly in AL amyloidosis 
patients, in whom NT-proBNP is a sensitive marker of cardiac involvement. 
Clinical Scenario #2: Screening for Cardiac Amyloidosis: New Symptomatic Heart Failure 
In the nine clinical indications encompassing patients with new symptomatic heart failure considered in 
this document, echocardiography and CMR were rated as uniformly “Appropriate” for screening for 
cardiac amyloidosis. This is consistent with the appropriate rating given to CMR and echocardiography 
for evaluation of newly suspected heart failure in the most recent appropriate utilization report 
addressing heart failure.(18) 99mTc-PYP/DPD/HMDP scintigraphy was also “Appropriate” for all of these 
indications except the two addressing patients in whom AL cardiac amyloidosis is suspected due to 
elevated FLC levels or monoclonal gammopathy, in whom bone scintigraphy alone is insufficient to 
establish the type of cardiac amyloidosis and for whom a biopsy is required. 99mTc-PYP/DPD/HMDP 
scintigraphy may occasionally be considered prior to endomyocardial biopsy in instances where ATTR 
cardiac amyloidosis is in the differential diagnosis. The panel discussed that individuals with unexplained 
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peripheral sensorimotor neuropathy should have diabetes mellitus and other causes of neuropathy 
excluded as a cause and may benefit from FLC level testing or genetic sequencing of amyloidogenic 
proteins to guide need for imaging. 
Clinical Scenario #3 and #4: Evaluation of Biopsy-Proven AL and ATTR Cardiac Amyloidosis 
Although biopsy-proven AL and ATTR cardiac amyloidosis qualifies as a definitive diagnosis, imaging was 
still considered to assess amyloid burden, response to therapy, or eligibility for stem cell transplant. For 
these indications, 99mTc-PYP/DPD/HMDP scintigraphy is not performed clinically and was rated as 
“Rarely Appropriate.” For quantifying cardiac amyloid burden, echocardiography and CMR were rated as 
“Appropriate.” With regard to assessing cardiac response to therapy and disease progression in AL and 
ATTR cardiac amyloidosis, the raters agreed that assessment every 24 months was “Appropriate.” More 
frequent evaluation varied across expert amyloidosis centers. 
Clinical Scenarios #5: Follow-Up Testing: New or Worsening Cardiac Symptoms 
In TTR gene carriers or patients with AL or ATTR amyloidosis who have new or worsening cardiac 
symptoms, the panel rated echocardiography, CMR, and 99mTc-PYP/DPD/HMDP scintigraphy as 
“Appropriate.” 99mTc-PYP/DPD/HMDP scintigraphy was rated as “Rarely Appropriate” for patients with 
AL amyloidosis. Notably, ATTR cardiac amyloidosis has been reported in long-term survivors of AL 
amyloidosis, and 99mTc-PYP/DPD/HMDP scintigraphy may have a potential role in those rare 
instances.(37) 
Clinical Scenarios #6: Other Indications and Prior Testing 
The rating panel evaluated several clinical indications emerging as high risk for potential cardiac 
amyloidosis and rated echocardiography as “Appropriate” and CMR and 99mTc-PYP/DPD/HMDP 
scintigraphy as “May Be Appropriate.” The evolving literature suggesting possible ATTR cardiac 
amyloidosis in patients with bilateral carpal tunnel syndrome, biceps tendon rupture, and unexplained 
neuropathy suggest that CMR and 99mTc-PYP/DPD/HMDP scintigraphy likely have a clinical role. 
However, the panel chose a rating of “May Be Appropriate” due to the lack of definitive evidence and 
the need for more research to clarify the prevalence of cardiac amyloidosis and the role of imaging in 
these subgroups and other emerging high-risk cohorts (e.g., transcutaneous aortic valve replacement 
(TAVR),(5) hip and knee arthroplasty(38)). 
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Clinical Scenarios #7: Prior Testing Suggestive of Cardiac Amyloidosis 
In patients with an echocardiogram suggestive of cardiac amyloidosis, CMR was rated as “Appropriate” 
and likewise echocardiography was “Appropriate” with a suggestive CMR. 99mTc-PYP/DPD/HMDP 
scintigraphy was rated as “May Be Appropriate,” as its use should be limited to suspected cases of ATTR 
cardiac amyloidosis. It should be noted that the most common clinical scenario is an older adult with an 
echo consistent with cardiac amyloidosis; in this group, the best test would likely be 99mTc-
PYP/DPD/HMDP scintigraphy due to the high incidence of ATTR cardiac amyloidosis. 
SUMMARY 
In Part 2 of this consensus statement, a panel of international experts have established the diagnostic 
criteria, clinical indications, and appropriate utilization of echocardiography, CMR, and radionuclide 
imaging for the assessment of cardiac amyloidosis. We hope that prospective clinical trials will validate 




Table 1. Expert Consensus Recommendations for Diagnosis of Cardiac 
Amyloidosis 
Criteria for Diagnosis Subtype 
Histological Diagnosis of Cardiac Amyloidosis: Endomyocardial Biopsy* 
1. Endomyocardial biopsy positive for cardiac amyloidosis with Congo red staining 
with apple-green birefringence under polarized light; typing by 
immunohistochemistry and/or mass spectrometry at specialized centers 
AL, ATTR, Other 
subtypes 
Histological Diagnosis of Cardiac Amyloidosis: Extracardiac Biopsy 
1. ATTR cardiac amyloidosis is diagnosed when below criteria are met: 
a. Extracardiac biopsy proven ATTR amyloidosis AND  
b. Typical cardiac imaging features (as defined below) 
ATTR 
2. AL cardiac amyloidosis is diagnosed when below criteria are met: 
a. Extracardiac biopsy proven AL amyloidosis AND  
b. Typical cardiac imaging features (as defined below) OR 
c. Abnormal cardiac biomarkers: abnormal age-adjusted NT-pro BNP or 
abnormal Troponin T/I/Hs-Troponin with all other causes for these changes 
excluded  
AL 
Clinical Diagnosis of ATTR Cardiac Amyloidosis: 99mTc-PYP, DPD, HMDP 
3. ATTR cardiac amyloidosis is diagnosed when below criteria are met: 
a. 99mTc-PYP, DPD, HMDP Grade 2 or 3 myocardial uptake of radiotracer AND  
b. Absence of a clonal plasma cell process as assessed by serum FLCs and serum 
and urine immunofixation AND 
c. Typical cardiac imaging features (as defined below) 
ATTR 
Typical Imaging Features of Cardiac Amyloidosis  
Typical cardiac echo or CMR or PET features: ANY of the below imaging features with all other causes for 
these cardiac manifestations, including hypertension, reasonably excluded. 
1. Echo 
a. LV wall thickness >12 mm  
b. Relative apical sparing of global LS ratio (average of apical LS/average of 
combined mid+basal LS >1) 
c. ≥ Grade 2 diastolic dysfunction†  
ATTR/AL 
2. CMR  
a. LV wall thickness >ULN for sex on SSFP cine CMR 
b. Global ECV >0.40  
c. Diffuse LGE† 
d. Abnormal gadolinium kinetics typical for amyloidosis, myocardial nulling prior 
to blood pool nulling 
ATTR/AL 
 
3. PET: 18F-florbetapir† or 18F-florbetaben PET† ‡ 
a. Target to background (LV myocardium to blood pool) ratio >1.5 
b. Retention index >0.030 min-1 
ATTR/AL 
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AL = amyloidogenic light chain; ATTR = amyloidogenic transthyretin; ECV = extracelullar volume; LGE = 
late gadolinium enhancement; LS = longitudinal strain; LV = left ventricular; SSFP, steady-state free 
precession; ULN = upper limit of normal, per reference (39) at mid-cavity level ULN for women/men were 
7mm/9mm (long axis) and 7mm/8mm (short axis), respectively.  
These consensus recommendations were based on moderate-quality evidence from one or more well-
designed, well-executed nonrandomized studies, observational studies, registries, or meta-analyses of 
such studies. The PET recommendations were based on more limited data. 
 
* Endomyocardial biopsy should be considered in cases of equivocal 99mTc-PYP, DPD, HMDP scan. When 
99mTc-PYP, DPD, HMDP is positive in the context of any abnormal evaluation for serum/urine 
immunofixation or serum free light chain assay, or MGUS, this should not be seen as diagnostic for ATTR 
cardiac amyloidosis. In these instances, referral to a specialist amyloid center for further evaluation and 
consideration of biopsy is recommended.  
 
† Off-label use of FDA-approved commercial products. 
‡18F-flutemetamol not studied systematically in the heart. 11C-Pittsurgh B compound is not FDA approved 





Table 2. Appropriate Utilization Rating of Multimodality Imaging for the 
Assessment of Cardiac Amyloidosis 











1. Identifying cardiac involvement: No cardiac symptoms 
1.1 Asymptomatic TTR gene carrier, 
initial evaluation 
A (7) M (6) A (8) 
1.2 Asymptomatic TTR gene carrier, 
recurrent testing 
A (7) M (6) A (7.5) 
1.3 Biopsy-proven systemic AL 
amyloidosis: NT-proBNP  
age-adjusted abnormal or 
troponin abnormal 
A (9) A (7) R (1) 
1.4 MGUS with abnormal FLC levels: 
NT-proBNP age-adjusted 
abnormal or troponin abnormal 
A (8) A (7) R (2) 
2. Screening for cardiac amyloidosis: New symptomatic heart failure 
2.1 Individuals of any age with 
elevated FLC levels 
A (9) A (8) R (2.5) 
2.2 African-Americans age >60 years 
with unexplained heart failure  
A (9) A (8) A (8) 
2.3 African-Americans age >60 years 
with unexplained increased LV 
wall thickness 
A (9) A (8) A (9) 
2.4 Non-African-Americans age >60 
years with unexplained heart 
failure and increased LV wall 
thickness 
A (9) A (8) A (8) 
2.5 Individuals >60 years with low- 
flow-low gradient aortic 
stenosis** 
NA A (8) A (7) 
2.6 Individuals with heart failure 
and unexplained peripheral 
sensorimotor neuropathy 
A (8) A (8) A (8) 
2.7 Individuals with known or 
suspected familial amyloidosis 
A (8) A (8) A (8) 
2.8 Individuals with monoclonal 
gammopathy, including multiple 
myeloma 
A (8) A (8) R (2) 
3. Evaluation of biopsy-proven AL cardiac amyloidosis 
3.1 Quantify cardiac amyloid burden A (7) A (9) R (1) 
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3.2 Assess cardiac response to 
therapy/disease progression in 
AL cardiac amyloidosis every  
6 months*  
M (5) † R (3) R (1) 
3.3 Assess cardiac response to 
therapy/disease progression in 
AL cardiac amyloidosis every  
12 months* 
M (5) M (6) R (1) 
3.4 Assess cardiac response to 
therapy/disease progression in 
AL cardiac amyloidosis every  
24 months* 
A (7) A (8) R (1) 
3.5 Guide eligibility for stem cell 
transplant in systemic AL 
amyloidosis 
A (8) M (5) R (1) 
4. Evaluation of biopsy-proven ATTR cardiac amyloidosis 
4.1 Quantify amyloid burden A (8) A (9) R (2) 
4.2 Assess cardiac response to 
therapy/disease progression in 
ATTR cardiac amyloidosis every 
6 months* 
M (4) † R (2) R (2) 
4.3 Assess cardiac response to 
therapy/disease progression in 
ATTR cardiac amyloidosis every 
12 months* 
A (7) M (5) R (2.5) 
4.4 Assess cardiac response to 
therapy/disease progression in 
ATTR cardiac amyloidosis every 
24 months* 
A (8) A (8) R (3) 
4.5 Contraindication to CMR 
(intracardiac devices or renal 
insufficiency) 
A (8) NA R (3) 
5. Follow-up testing: New or worsening cardiac symptoms 
5.1 TTR gene carrier A (8) A (7) A (8) 
5.2 AL amyloidosis A (8) A (7) R (1) 
5.3 ATTR amyloidosis A (8) A (7) A (7.5) 
6. Other clinical conditions associated with amyloidosis 
6.1 Individuals >60 years with 
unexplained bilateral carpal 
tunnel syndrome 
A (7) M (5) † M (6.5) † 
6.2 Individuals with unexplained 
bilateral carpal tunnel syndrome 
and elevated FLC levels 
A (7) M (5) M (5.5) 
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6.3 Individuals >60 years with heart 
failure and unexplained biceps 
tendon rupture 
A (7) M (5) M (6) 
6.4 Adults, especially elderly men, 
with unexplained neuropathy, 
other arrhythmias in the 
absence of usual risk factors and 
no signs/symptoms of  
heart failure 
A (7) M (5) M (6) 
7. Prior testing suggestive of cardiac amyloidosis 
7.1 Suggestive echo NA A (7) M (6) 
7.2 Suggestive CMR A (8) NA M (6) 
7.3 Suggestive bone scintigraphy  A (8) A (7.5) NA 
A = appropriate; AL = amyloidogenic light chain; ATTR = amyloidogenic transthyretin; bone scintigraphy = 99mTc 
pyrophosphate (PYP), 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD), 99mTc-hydroxymethylene 
diphosphonate (HMDP); CMR = cardiac magnetic resonance; Echo = echocardiography; LV = left ventricular; MGUS 
= Monoclonal gammopathy of uncertain significance; M = maybe appropriate; NA = not assessed; NT-pro BNP = N-
terminal pro-brain natriuretic peptide; R= rarely appropriate.  
* = Time interval may vary based on the clinical status of the patient and local clinical practice. 
† = indicates lack of consensus for rating among experts. 
** = Although most patients with cardiac amyloidosis will have preserved LV ejection fraction or “paradoxical” low-
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